Novo Nordisk

Guidelines emphasize prompt intervention for suspected bleeds.

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is indicated for: Treatment of bleeding episodes and perioperative management in adults and children with congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.

NovoSeven^® RT is the #1 prescribed bypassing agent used in hospitals²

Addressing bleeds, whenever they occur

A well-established safety profile

•	Low rate of thrombotic events based on clinical trials and registry data³

◦

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance. Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in CHwI, 4% in AH, 0.8% in CFVIId, and <0.2% in GT with refractoriness to platelets.³

Proven effective for bleed resolution and surgery across 5 indications³

•	CHAwI, CHBwI, AH, GT with refractoriness to platelet transfusions, and CFVIId

Product features that support hospital use

•	Low-volume dosing and compact packaging to help maximize space³

With NovoSeven^® RT, the experience continues

•	>35 years of clinical experience^4,a

Learn More

AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors; CHwI=congenital hemophilia with inhibitors; GT=Glanzmann’s thrombasthenia.

^a1988: compassionate use initiated in the United States; 1999: FDA approval received for CHwI.^3,5

Scroll to see how NovoSeven^® RT continues to support your patients.

Important Safety Information

WARNING: THROMBOSIS

•	Serious arterial and venous thrombotic events following administration of NovoSeven^® RT have been reported

•	Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT

•	Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

•	Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance

•

Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Please click here or scroll below for additional Important Safety Information.

Proven effective for bleed resolution and surgery across 5 indications—more than any other product^3,6-8

This chart is not intended to compare efficacy or safety.

^bObizur^® is contraindicated in patients with congenital hemophilia A with inhibitors.⁷
^cFor patients aged 12 years and older.⁸

Why NovoSeven^® RT

To learn more right away, request a call with your Rare Blood Institutional Account Manager.

Have you created an account on novoMEDLINK™?

Keep up with important information about treatments for rare bleeding disorders.

Receive the latest news about rare bleeding disorders from Novo Nordisk.

Download, order, and share educational materials for you and your patients.

Create Your Account

Indications and Usage

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

•	Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets

•	Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information (cont’d)

Warnings and Precautions

•

Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven^® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur

•

Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed

•	Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

•

The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven^® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

•	Thrombosis may occur if NovoSeven^® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information, including Boxed Warning.

References:

1.	Data on file as of 2020. Novo Nordisk, Inc; Plainsboro, NJ.
2.	Data on file as of 2025. Novo Nordisk, Inc; Plainsboro, NJ.
3.	NovoSeven^® RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
4.	Hedner U. History of rFVIIa therapy. Thromb Res. 2010;125(suppl 1):S4-S6.
5.	Neufeld EJ, Négrier C, Arkhammar P, et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015;29(suppl1):S34-S41.
6.	FEIBA^® [package insert]. Lexington, MA: Baxalta US Inc.; 2024.
7.	Obizur^® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2024.
8.	SEVENFACT^® [package insert]. Louisville, KY: HEMA Biologics, LLC; 2025.

Please click on the link to see WAC pricing for the product mentioned above: Product Pricing.

Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.

NovoSeven^® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2026 Novo Nordisk All rights reserved. US26NSVN00012 July 2026